Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mismatch Repair Deficient or MSI-High Solid Tumors”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)WithdrawnNCT04001101
What this trial is testing

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Who this might be right for
Microsatellite Instability HighMismatch Repair DeficiencyColorectal Cancer
University of Colorado, Denver
Testing effectiveness (Phase 2)Looking for participantsNCT06362369
What this trial is testing

Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Who this might be right for
Advanced CancerAdvanced Solid TumorMelanoma+15 more
7 Hills Pharma, LLC 126
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07259473
What this trial is testing

Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMismatch Repair Deficient or MSI-High Solid TumorsImmunotherapy
Shanghai Zhongshan Hospital 15
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Early research (Phase 1)Ended earlyNCT04458259
What this trial is testing

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Who this might be right for
Neoplasm Metastasis
Pfizer 88
Early research (Phase 1)Study completedNCT03236935
What this trial is testing

Phase Ib of L-NMMA and Pembrolizumab

Who this might be right for
Non-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell Carcinoma+3 more
The Methodist Hospital Research Institute 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200559
What this trial is testing

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Who this might be right for
Epithelial Ovarian Cancer
Alexander B Olawaiye, MD 25
Testing effectiveness (Phase 2)Looking for participantsNCT03941574
What this trial is testing

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Who this might be right for
MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech 108
Testing effectiveness (Phase 2)Ended earlyNCT04547101
What this trial is testing

AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Who this might be right for
MSI-H/dMMR Solid Tumor
Akeso 6
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Early research (Phase 1)Looking for participantsNCT07403721
What this trial is testing

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Who this might be right for
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen 464
Testing effectiveness (Phase 2)Looking for participantsNCT07213609
What this trial is testing

Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Who this might be right for
Neoplasms, ColorectalNeoplasms
GlaxoSmithKline 47
Not applicableNot Yet RecruitingNCT07625735
What this trial is testing

MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMismatch Repair Deficient or MSI-High Solid TumorsLymph Node Metastasis+1 more
Shanghai Zhongshan Hospital 3,000
Early research (Phase 1)Not Yet RecruitingNCT07552376
What this trial is testing

This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.

Who this might be right for
MSI-H or dMMR Advanced Solid Tumors
Shanghai Qilu Pharmaceutical Research and Development Center LTD 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07266025
What this trial is testing

Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study

Who this might be right for
Gastric AdenocarcinomaGastroesophageal AdenocarcinomaMismatch Repair Deficient or MSI-High Solid Tumors+1 more
Shanghai Zhongshan Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT03736889
What this trial is testing

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Who this might be right for
MSI-H/dMMR Solid Tumors
BeiGene 200
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110
Testing effectiveness (Phase 2)Looking for participantsNCT06047379
What this trial is testing

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Who this might be right for
Diffuse Astrocytoma, IDH-MutantGlioblastoma, IDH-wildtypeBrain Metastases, Adult+18 more
Neonc Technologies, Inc. 134
Early research (Phase 1)Ended earlyNCT06625515
What this trial is testing

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentColorectal Cancer Metastatic+3 more
Accent Therapeutics 17
Early research (Phase 1)Study completedNCT03894618
What this trial is testing

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Squamous Cell Carcinoma of the Head and NeckMelanomaNon Small Cell Lung Cancer+10 more
Shattuck Labs, Inc. 49
Load More Results